
Halozyme Therapeutics, Inc. – NASDAQ:HALO
Halozyme Therapeutics stock price today
Halozyme Therapeutics stock price monthly change
Halozyme Therapeutics stock price quarterly change
Halozyme Therapeutics stock price yearly change
Halozyme Therapeutics key metrics
Market Cap | 5.94B |
Enterprise value | 6.24B |
P/E | 24.82 |
EV/Sales | 9.45 |
EV/EBITDA | 19.78 |
Price/Sales | 7.52 |
Price/Book | 29.27 |
PEG ratio | -0.51 |
EPS | 2.46 |
Revenue | 862.98M |
EBITDA | 461.18M |
Income | 318.80M |
Revenue Q/Q | 20.80% |
Revenue Y/Y | 22.41% |
Profit margin | 30.62% |
Oper. margin | 40.53% |
Gross margin | 78.9% |
EBIT margin | 40.53% |
EBITDA margin | 53.44% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHalozyme Therapeutics stock price history
Halozyme Therapeutics stock forecast
Halozyme Therapeutics financial statements
$52
Potential downside: -25.71%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 221.03M | 74.75M | 33.82% |
---|---|---|---|
Sep 2023 | 216.03M | 81.83M | 37.88% |
Dec 2023 | 230.03M | 85.38M | 37.12% |
Mar 2024 | 195.87M | 76.82M | 39.22% |
Jun 2023 | 1810440000 | 1.65B | 91.66% |
---|---|---|---|
Sep 2023 | 1892662000 | 1.64B | 86.83% |
Dec 2023 | 1733270000 | 1.64B | 95.16% |
Mar 2024 | 1841527000 | 1.66B | 90.34% |
Jun 2023 | 66.84M | 54.99M | 2.44M |
---|---|---|---|
Sep 2023 | 132.41M | -83.45M | 4.10M |
Dec 2023 | 102.35M | -8.29M | -249.92M |
Mar 2024 | 129.42M | -82.68M | -489K |
Halozyme Therapeutics alternative data
Aug 2023 | 393 |
---|---|
Sep 2023 | 393 |
Oct 2023 | 393 |
Nov 2023 | 393 |
Dec 2023 | 393 |
Jan 2024 | 393 |
Feb 2024 | 393 |
Mar 2024 | 373 |
Apr 2024 | 373 |
May 2024 | 373 |
Jun 2024 | 373 |
Jul 2024 | 373 |
Halozyme Therapeutics other data
Period | Buy | Sel |
---|---|---|
Nov 2023 | 0 | 11708 |
Dec 2023 | 0 | 20000 |
Jan 2024 | 0 | 10000 |
Feb 2024 | 0 | 20000 |
Mar 2024 | 0 | 20000 |
Apr 2024 | 0 | 20000 |
May 2024 | 0 | 20000 |
Jun 2024 | 0 | 60000 |
Jul 2024 | 0 | 25000 |
Aug 2024 | 0 | 79881 |
Sep 2024 | 0 | 80000 |
Oct 2024 | 0 | 40000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 10,000 | $19.98 | $199,800 | ||
Option | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 10,000 | $19.98 | $199,800 | ||
Sale | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 10,000 | $53.26 | $532,590 | ||
Sale | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 10,000 | $53.26 | $532,590 | ||
Option | LABARRE MICHAEL J. officer: SVP, CHI.. | Option to Purchase Common Stock | 10,000 | $19.98 | $199,800 | ||
Option | LABARRE MICHAEL J. officer: SVP, CHI.. | Option to Purchase Common Stock | 10,000 | $19.98 | $199,800 | ||
Option | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 5,509 | $16.65 | $91,725 | ||
Option | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 5,509 | $16.65 | $91,725 | ||
Sale | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 9,923 | $53.74 | $533,292 | ||
Sale | LABARRE MICHAEL J. officer: SVP, CHI.. | Common Stock | 9,923 | $53.74 | $533,292 |
Quarter | Transcript |
---|---|
Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 20 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. (1963) Pres, Chief Executive Officer & Director | $1,520,000 |
Ms. Elaine D. Sun (1972) Senior Vice President & Chief Financial Officer | $859,580 |
Dr. Michael J. LaBarre (1964) Senior Vice President & Chief Technical Officer | $710,180 |
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme: Recent Approvals Alter My Appetite
PeptiDream: Opulent Dream Now A Reality
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA Setback
Halozyme: Inflection Point With argenx's Vyvgart SC Approval (Reiterating Buy)
Halozyme Therapeutics: Pharma With Growing Royalty Revenue And Product Income
-
What's the price of Halozyme Therapeutics stock today?
One share of Halozyme Therapeutics stock can currently be purchased for approximately $70.
-
When is Halozyme Therapeutics's next earnings date?
Unfortunately, Halozyme Therapeutics's (HALO) next earnings date is currently unknown.
-
Does Halozyme Therapeutics pay dividends?
No, Halozyme Therapeutics does not pay dividends.
-
How much money does Halozyme Therapeutics make?
Halozyme Therapeutics has a market capitalization of 5.94B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 25.62% to 829.25M US dollars.
-
What is Halozyme Therapeutics's stock symbol?
Halozyme Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HALO".
-
What is Halozyme Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Halozyme Therapeutics?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Halozyme Therapeutics's key executives?
Halozyme Therapeutics's management team includes the following people:
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. Pres, Chief Executive Officer & Director(age: 62, pay: $1,520,000)
- Ms. Elaine D. Sun Senior Vice President & Chief Financial Officer(age: 53, pay: $859,580)
- Dr. Michael J. LaBarre Senior Vice President & Chief Technical Officer(age: 61, pay: $710,180)
-
How many employees does Halozyme Therapeutics have?
As Jul 2024, Halozyme Therapeutics employs 373 workers.
-
When Halozyme Therapeutics went public?
Halozyme Therapeutics, Inc. is publicly traded company for more then 21 years since IPO on 16 Mar 2004.
-
What is Halozyme Therapeutics's official website?
The official website for Halozyme Therapeutics is halozyme.com.
-
Where are Halozyme Therapeutics's headquarters?
Halozyme Therapeutics is headquartered at 11388 Sorrento Valley Road, San Diego, CA.
-
How can i contact Halozyme Therapeutics?
Halozyme Therapeutics's mailing address is 11388 Sorrento Valley Road, San Diego, CA and company can be reached via phone at 858 794 8889.
-
What is Halozyme Therapeutics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Halozyme Therapeutics in the last 12 months, the avarage price target is $52. The average price target represents a -25.71% change from the last price of $70.
Halozyme Therapeutics company profile:

Halozyme Therapeutics, Inc.
halozyme.comNASDAQ
373
Biotechnology
Healthcare
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
San Diego, CA 92121
CIK: 0001159036
ISIN: US40637H1095
CUSIP: 40637H109